SubsidieMeestersValidation of a new drug target in non-alcoholic steatohepatitis
This project aims to explore oxidative stress's role in non-alcoholic steatohepatitis (NASH) and develop new treatments by targeting MAP kinases p38 and JNK.
Projectdetails
Introduction
This research focuses on the increasing prevalence of metabolic liver disease, specifically non-alcoholic steatohepatitis (NASH), which is driven by obesity, diabetes, and its related causal connections.
Medical Challenge
NASH is a significant medical challenge with no approved treatments, causing a substantial economic burden.
Research Objectives
The project aims to investigate the role of oxidative stress in NASH development and progression.
Targeted Mechanisms
By targeting the MAP kinases p38 and JNK, which drive the inflammatory and fibrotic aspects of NASH, our research could lead to new treatment approaches.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-6-2023 |
| Einddatum | 30-11-2024 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- KOBENHAVNS UNIVERSITETpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Understanding Metabolic Activation of Dendritic Cells in Non-Alcoholic Fatty Liver DiseaseThis project aims to investigate the role of conventional dendritic cells in non-alcoholic steatohepatitis by exploring their immuno-metabolic functions and interactions with liver metabolism. | ERC Starting... | € 2.406.250 | 2022 | Details |
Scalable target identification for metabolic liver diseaseThe 3DMASH project aims to identify novel pharmacological targets for metabolic dysfunction-associated steatohepatitis by mapping tissue interactions using patient-derived organotypic cultures. | ERC Consolid... | € 1.950.000 | 2025 | Details |
Vascular Control of NASH ProgressionThis project aims to characterize the gut-liver vasculature in NASH progression using spatial sorting and imaging to identify therapeutic targets and prognostic markers for HCC. | ERC Consolid... | € 1.741.250 | 2024 | Details |
A novel NASH model for target and drug candidate identificationThe SPHERO-NASH project aims to develop a 3D liver model for studying NASH mechanisms and drug discovery, facilitating commercialization of novel therapeutic targets and compounds. | ERC Proof of... | € 150.000 | 2023 | Details |
FATty liver disease and Gutmicrobial Alcohol Production (FATGAP)FATGAP aims to investigate the link between gut microbiota, dietary fructose, and NAFLD-NASH, exploring pH effects and developing engineered bacteria for potential treatment. | ERC Advanced... | € 2.875.663 | 2024 | Details |
Understanding Metabolic Activation of Dendritic Cells in Non-Alcoholic Fatty Liver Disease
This project aims to investigate the role of conventional dendritic cells in non-alcoholic steatohepatitis by exploring their immuno-metabolic functions and interactions with liver metabolism.
Scalable target identification for metabolic liver disease
The 3DMASH project aims to identify novel pharmacological targets for metabolic dysfunction-associated steatohepatitis by mapping tissue interactions using patient-derived organotypic cultures.
Vascular Control of NASH Progression
This project aims to characterize the gut-liver vasculature in NASH progression using spatial sorting and imaging to identify therapeutic targets and prognostic markers for HCC.
A novel NASH model for target and drug candidate identification
The SPHERO-NASH project aims to develop a 3D liver model for studying NASH mechanisms and drug discovery, facilitating commercialization of novel therapeutic targets and compounds.
FATty liver disease and Gutmicrobial Alcohol Production (FATGAP)
FATGAP aims to investigate the link between gut microbiota, dietary fructose, and NAFLD-NASH, exploring pH effects and developing engineered bacteria for potential treatment.